anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Atropine is a reversible antagonist of muscarine-like actions of acetyl-choline and is therefore classified as an antimuscarinic agent. Atropine is relatively selective for muscarinic receptors. Its potency at nicotinic receptors is much lower, and actions at non-muscarinic receptors are generally undetectable clinically. Atropine does not distinguish among the M1, M2, and M3 subgroups of muscarinic receptors.

The pupillary constrictor muscle depends on muscarinic cholinoceptor activation. This activation is blocked by topical atropine resulting in unopposed sympathetic dilator activity and mydriasis. Atropine also weakens the contraction of the ciliary muscle, or cycloplegia. Cycloplegia results in loss of the ability to accommodate such that the eye cannot focus for near vision.
Papillary thyroid carcinoma (PTC) is characterized by T cell infiltration and frequently by the presence of anti-thyroglobulin antibodies (TgAbs). The role of cellular immunity and of TbAbs in this context is a matter of debate. The aim of our study was to correlate the presence of TgAbs, tumor epitope-specific T cells and the clinical outcome of PTC patients. We studied n=183 consecutive patients with a diagnosis of PTC which were treated with total thyroidectomy plus 131I ablation. During a follow-up of in mean 97 months, most of the PTC patients had no signs of tumor relapse (n=157 patients). In contrast, one patient had serum Tg levels above the detection limit and<1 ng/ml, two patients Tg serum levels≥1 ng/ml and<2 ng/ml and n=23 patients had Tg serum levels≥2 ng/ml. Morphological signs of tumor recurrence were seen in 14 patients; all of these patients had serum Tg levels≥2 ng/ml. Importantly, with the exception of one patient, all TgAb positive PTC patients (n=27) had no signs of tumor recurrence as the serum Tg levels were below the assays functional sensitivities. Tetramer analyses revealed a higher number of tumor epitope-specific CD8+T cells in TgAb positive patients compared to TgAb negative PTC patients. In summary, we show that the occurrence of TgAbs may have an impact on the clinical outcome in PTC patients. This might be due to a tumor epitope-specific cellular immunity in PTC patients.
A patient will be given CM 1 cc / cm3. After 3 weeks, the patient will be given CM 1 cc / cm3. The maximum size of Keloid is 15 cm per patient.
BACKGROUND: Information regarding late recurrence after pulmonary resection for non-small cell lung cancer (NSCLC) is limited. This study aimed to analyze the risk factors for late recurrence after surgery for NSCLC in the current era.
PATIENTS AND METHODS: We conducted a retrospective study of patients who underwent complete resection for pathological I-III NSCLC between 2006 and 2015. Late recurrence was defined as a recurrence that met the following conditions: (1) the patient underwent chest computed tomography (CT) at or after 54 months after surgery and recurrence was not detected at that time, and (2) recurrence that occurred more than 5 years after surgery. The factors influencing late recurrence, relapse-free survival (RFS), and overall survival (OS) after surgery were analyzed.
RESULTS: A total of 1275 with 5-year relapse-free survival after surgery were enrolled in this study. The mean age of the patients was 66.4 years and 54% of the patients were men. The median interval between surgery and the latest follow-up examination was 98 months. In total, 35 patients (2.7%) experienced late recurrence and 138 patients have died thus far. The cumulative recurrence, RFS, and OS rates at 10 years were 3.9%, 84.9%, and 86.3%, respectively. A multivariate analysis revealed that pleural invasion was an independent risk factor for late recurrence. Pleural invasion was a poor prognostic factor for both RFS and OS.
CONCLUSIONS: Pleural invasion was a predictor of late recurrence. Age > 67 years, preoperative serum carcinoembryonic antigen (CEA) > 5 ng/ml, non-adenocarcinoma, and pleural invasion were poor prognostic factors for RFS.
INTRODUCTION: Posterior Urethral Stenosis (PUS) is a surgical challenge. The aim of this article is to summarize current knowledge on the management of PUS.
MATERIAL AND METHODS: A comprehensive literature review was conducted using the PubMed database, covering the period from 2020 to 2023. To supplement this review, recommendations from the American Urological Association (AUA), European Association of Urology (EAU), and Canadian Urological Association (CUA), along with several key reference surgical guides, were incorporated. The collected data was then summarized by etiology to provide a detailed analysis.
RESULTS: Pelvic Fracture Urethral Injury (PFUI) is a frequent complication of pelvic fractures. Treatments are well-established, including early realignment and excision-primary-anastomosis (EPA). Stenosis following treatment for benign prostatic hyperplasia (BPH) presents specific challenges due to the high risk of urinary incontinence. The management of post-prostatectomy stenoses stenosis depends on the stricture's location and may involve endoscopic treatment or complex reconstruction. Stenosis following radiotherapy presents additional complexity due to poor tissue quality. The impact on urinary and sexual function varies by etiology and must be considered when choosing a treatment approach.
CONCLUSION: The management of PUS must consider the precise location and etiology of the stenosis. Treatment options vary from endoluminal techniques to open or robot-assisted reconstructions, chosen based on the patient's goals and overall health condition. Special attention must be given to the potential impact on urinary and sexual function.
In Phase 1 (Dose Escalation), patients will be randomized to either once-weekly (Arm A) or twice- weekly (Arm B) dosing with selinexor. Dose escalation will be performed within each arm for both lenalidomide and selinexor to determine the selinexor MTD for that arm. Each arm will be expanded until approximately 17 patients have been treated at the MTD in each arm. The Sponsor and Investigator will review the MTD, efficacy, and safety data from Phase 1 to determine which dose schedule (Arm A or B) to be used as the RP2D dose in the Expansion Phase.

In Phase 2 (Expansion), patients who had received the MTD dose that was nominated for RP2D will continue at the same dose. Patients who did not receive the RP2D for that arm will stay on their Phase 1 dose. Additional patients will be accrued, as needed, to achieve the target population size of approximately 34 patients at the RP2D.
(SEE TABLE BELOW):

Carbamazepine oral suspension in combination with liquid chlorpromazine or thioridazine results in precipitate formation, and, in the case of chlorpromazine, there has been a report of a patient passing an orange rubbery precipitate in the stool following coadministration of the two drugs (see PRECAUTIONS, Drug Interactions). Because the extent to which this occurs with other liquid medications is not known, carbamazepine oral suspension should not be administered simultaneously with other liquid medications or diluents. Monitoring of blood levels has increased the efficacy and safety of anticonvulsants (see PRECAUTIONS, Laboratory Tests). Dosage should be adjusted to the needs of the individual patient. A low initial daily dosage with a gradual increase is advised. As soon as adequate control is achieved, the dosage may be reduced very gradually to the minimum effective level. Medication should be taken with meals.

Since a given dose of carbamazepine oral suspension will produce higher peak levels than the same dose given as the tablet, it is recommended to start with low doses (children 6 to 12 years: 1/2 teaspoon four times a day) and to increase slowly to avoid unwanted side effects.

Conversion of patients from oral carbamazepine tablets to carbamazepine oral suspension: Patients should be converted by administering the same number of mg per day in smaller, more frequent doses (i.e., twice a day tablets to three times a day suspension).
Anxiety Sensitivity (AS) refers to an individual's fear of experiencing anxiety-related symptoms (e.g., dyspnea or heart palpitations) and is a core construct underlying the initiation and maintenance of pathological anxiety. Recent evidence suggests that reducing AS may be critical for the prevention and treatment of anxiety across diagnostic categories. Exposure therapy, an important component of cognitive behavioral therapy (CBT), is one of the most effective treatments for reducing AS, and has been shown to improve symptoms across a number of different anxiety disorders. Meta-analyses reveal an approximately 50% treatment response rate, with the remaining half of patients showing either no response or dropping out of treatment early. Unfortunately, there is a paucity of research exploring which variables predict treatment outcome and there are currently no tests for predicting which patients would benefit the most from exposure therapy. In this study, participants will complete two sessions of a carbon dioxide (CO2) habituation paradigm, a safe and noninvasive physiological test that entails repeated exposures to single vital capacity inhalations of 20% CO2. Both CO2 testing sessions will be completed within a 72-hour time period. Patients then complete a 10-week group-based exposure therapy to determine whether an individual's degree of habituation to CO2 predicts treatment outcome.
OBJECTIVE: Visceral obesity and the lifetime risk of cardiovascular disease (CVD) have received increasing attention. However, the relationship between dynamic changes in visceral obesity and CVD has not been studied. We aimed to determine the association of visceral adiposity index (VAI) transition with CVD risk.
METHODS: A total of 5395 participants were recruited in 2011-2012 and followed up until 2018 from the China Health and Retirement Longitudinal Study. The cut-off value of the VAI was obtained by the receiver-operating characteristic curve. Participants were grouped based on VAI change patterns during the follow-up period (2011-2015): the low-low group, low-high group, high-low group, and high-high group. CVD was defined as a medical diagnosis of heart disease and/or stroke. A Cox proportional hazards model was used to evaluate the correlation between VAI transition and CVD.
RESULTS: Over a median follow-up period of 7 years, 969 participants (17.9 %) developed CVD. VAI change patterns were significantly associated with CVD risk after adjustment for demographic characteristics and risk factors. The high-high group (hazard ratio (HR): 1.65, 95 % confidence interval (CI): 1.39-1.97) and the low-high group (HR: 1.29, 95 % CI: 1.04-1.61) were associated with a higher risk of CVD after adjusting for demographic characteristics and traditional risk factors compared to the low-low group, while the effect in the high-low group was not significant.
CONCLUSIONS: VAI transition was significantly associated with the risk of CVD. Monitoring the dynamics of the VAI in public health practice would help prevent CVD.
Of all people diagnosed with cancer, 25% will have their cancer come back and spread to the bones. This often results in significant pain and suffering. Radiation treatment is often recommended as a safe and quick treatment that gives most people good relief from bone pain within a couple of weeks. However, some people can experience a short episode of increased pain called a flare a day or two after radiation treatment that lasts about a day. Studies suggest that around a third of all people who receive radiation treatment to help pain from cancer in the bones will have a pain flare. This study is being done because it would be helpful to prevent extra bone pain from happening to people after they receive radiation treatments. The purpose of this study is to find out if a medication called dexamethasone can help prevent pain flare as a result of radiation therapy.
The incidence of colorectal cancer (CRC) in patients under 50 has been increasing over the past several decades. The factors underlying the increase in early onset colorectal cancer (EOCRC) are not entirely clear, although several genetic and clinical differences with late onset colorectal cancer (LOCRC) have been noted. EOCRC cases are often diagnosed at a more advanced stage, raising the possibility that these cancers progress more rapidly than LOCRC cases. The impact of age on cancer progression is an intriguing topic and numerous lines of research have found that a young tissue environment is often more promotional. In fact, a less hospitable promotional tissue environment in older individuals may offset the increased cancer risk associated with the increased mutational load associated with age. Here we address how youthful aspects of angiogenesis, the tumor immune response, and the oxidative stress response may contribute to the rapid progression of EOCRC. Understanding the factors promoting EOCRC may provide insight into why EOCRC cases are increasing.
<P>PROBLEM TO BE SOLVED: To provide a substance having allergic disease suppressing action with improved safety and effectiveness and to safely and more effectively prevent and cure allergic diseases.  <P>SOLUTION: A water-soluble heteropolysaccharide produced by an acetobacter used in the production of food vinegar (e.g. Acetobacter polysaccharogenes and Acetobacter xylinum) and having high safety has functions to increase the production of IL-12 effective for suppressing the differentiation of Th2 cell producing cytokine participating in allergic reaction and to suppress the production of IL-4 and IgE from Th2 cell. A formulation for the prevention/treatment of allergic diseases is produced based on the above findings by using the water-soluble heteropolysaccharide as an active component. The formulation for the prevention/treatment of allergic diseases has high safety and improved effectiveness to radically cure the allergic reaction by suppressing the differentiation to the Th2 cell and is usable as foods, drinks and pharmaceuticals.  <P>COPYRIGHT: (C)2004,JPO
Participants in the experimental group will also be educated on the general use of the ActiGraph through verbal and written information and will be asked to wear the ActiGraph during week 0 for 3 consecutive days. The collected physical activity parameters will be the baseline data.Afterward, participants in the experimental group will be educated with the educational materials "How walking is beneficial to muscle mass and your health." And then the ActiGraph will be collected by the research assistant in order to analyze the physical activity parameters, including time spent walking and walking steps. A final assessment will be conducted at week 4. The participant will be reminded that the ActiGraph and the post-test questionnaires will be picked up at the end of week 4.
Dextrose Injection, USP solutions are sterile and nonpyrogenic. They are parenteral solutions containing various concentrations of dextrose in water for injection intended for intravenous administration.

Each 100 mL of 5% Dextrose Injection, USP, contains dextrose, hydrous 5 g in water for injection. The caloric value is 170 kcal/L. The osmolarity is 252 mOsmol/L (calc.), which is slightly hypotonic.

Each 100 mL of 10% Dextrose Injection, USP, contains dextrose, hydrous 10 g in water for injection. The caloric value is 340 kcal/L. The osmolarity is 505 mOsmol/L (calc.), which is hypertonic.

The pH for both concentrations is 4.3 (3.2 to 6.5).

The solutions contain no bacteriostat, antimicrobial agent or added buffer and each is intended only as a single-dose injection. When smaller doses are required the unused portion should be discarded.

The solutions are parenteral fluid and nutrient replenishers.

Dextrose, USP is chemically designated D-glucose monohydrate (C6H12O6• H2O), a hexose sugar freely soluble in water. It has the following structural formula:

Water for Injection, USP is chemically designated H2O.

The flexible plastic container is fabricated from a specially formulated polyvinylchloride. Water can permeate from inside the container into the overwrap but not in amounts sufficient to affect the solution significantly. Solutions in contact with the plastic container may leach out certain chemical components from the plastic in very small amounts; however, biological testing was supportive of the safety of the plastic container materials. Exposure to temperatures above 25°C/77°F during transport and storage will lead to minor losses in moisture content. Higher temperatures lead to greater losses. It is unlikely that these minor losses will lead to clinically significant changes within the expiration period.
The objective of this pilot phase II trial is to evaluate the ability of pirfenidone, a novel anti-fibrotic agent, to reduce the proteinuria and slow the rate of progression of renal insufficiency in patients with focal segmental glomerulosclerosis (FSGS). We will enroll 25 patients with renal biopsy proven FSGS and evidence of impaired renal function (glomerular filtration rate, GFR, of 10-80 ml/min; after 1/02 must have GFR greater than 25 ml/min) as assessed by the 4 variable Modification of Diet in Renal Disease equation. As standard of care therapy, all patients will also receive angiotensin converting enzyme inhibitor (ACEI) therapy, and will receive an HMG Co-A reductase inhibitor drug if hypercholesterolemic. Preliminary evaluation will assure that the patients meet the study requirements, and an evaluation period will be used to ensure that patients are on maximal conservative therapy prior to the baseline period. Patients will receive treatment with pirfenidone daily, with dose adjusted for body weight and level of kidney function. The primary end point will be the decrease glomerular filtration as a marker of glomerular injury; reduction in proteinuria will be a secondary end-point. If the pilot study suggests this drug delays progression of renal insufficiency or reduces proteinuria in patients with FSGS, we will proceed with a large scale randomized, placebo-controlled study.
PURPOSE: To obtain metal oxide flaky powder suitable for formulation as a colorant in cosmetics, safe to human body, excellent in light resistance, bleed resistance, heat resistance, etc., containing an organic pigment with high opacifying power. CONSTITUTION: The objective metal oxide flaky powder contains 0.5-40wt.% of an organic pigment (esp. pref. Red #226, Red #202, Red #203, Red #204). The metal oxide is pref. selected from silica, titania, alumina and zirconia. The flaky powder is obtained by the following process: a solution comprising water, an organic solvent, organic pigment and hydrolyzable organometallic compound subject to polycondensation is applied on a smooth-surfaced substrate, and the resultant film is peeled off and then heated at 80-250 deg.C for 5min to 24h. For the flaky powder, the organic pigment lies included and immobilized by the inorganic oxide; therefore, the organic pigment is seldom leached or eliminated from the flakes. The other objective cosmetic formulated with the flaky powder is excellent in perspiration resistance, etc.
The invention relates to the field of biomedicine. In particular, the present invention relates to an isolated polypeptide comprising a first and a second portion, the first portion comprising a chemokine or a functional fragment thereof, and the second portion comprising a binding partner capable of specifically binding to an antigen. More specifically, the chemokine is CCL 19. The invention also relates to nucleic acid molecules encoding the isolated polypeptides, vectors comprising the nucleic acid molecules, and host cells comprising the vectors. The invention further relates to methods for producing the isolated polypeptides. Finally, the invention relates to pharmaceutical compositions comprising the isolated polypeptides, nucleic acid molecules, vectors and/or host cells, in particular for killing tumor cells and for treating cancer.
A large group of heavily drug-exposed HIV-infected individuals with detectable HIV-1 RNA exists as a result of the sequential use and failure of existing antiretroviral agents from each of the 3 antiretroviral drug classes (nucleoside reverse transcriptase inhibitors \[NRTIs\], protease inhibitors \[PIs\], and nonnucleoside reverse transcriptase inhibitors \[NNRTIs\]). Systematic approaches are needed to define "salvage therapy" regimens for this patient group. This trial uses a short-term study to determine the initial safety, pharmacology, and antiviral potency of MMF in augmenting the antiretroviral effect of ABC, which then can be appraised for use as a salvage regimen. After rapid oral absorption, MMF is hydrolyzed to form MPA (mycophenolic acid), the active metabolite. Recent in vitro studies show that MPA concentrations as low as 62.5 nM synergistically increase the antiviral effect of ABC or ddI, or of ABC in combination with ddI, against multinucleoside-resistant HIV strains. These observations suggest that MMF in combination with ABC might play a role in antiretroviral therapy in patients with drug resistance, and continued clinical evaluation of MMF is warranted.

At study entry, patients stop current NRTIs but continue taking PIs and NNRTIs with study treatment. The first 50 patients are stratified by plasma HIV-1 RNA (below 40,000 copies/ml or 40,000 and higher copies/ml) and randomized to either Arm A or Arm B. Arm A receives ABC with MMF placebo; Arm B receives ABC and MMF. Only ABC and MMF are provided by the study. Treatment is received for 4 weeks and patients are evaluated for safety, tolerability, and virologic response. At Week 4, entry genotype results are provided to patients and antiretroviral therapy may then be altered as indicated. Patients are unblinded to study treatment as soon as possible after Week 4 but no later than Week 7. Future opening of Arm C to 125 additional patients is delayed until the first 50 patients have reached Week 4 and an interim review of safety and virologic response is completed. Responders may continue study treatment through Week 24. At 10 clinic visits patients have blood drawn for HIV-1 RNA determinations, CD4 and CD8 cell counts, and genotyping. Patients may participate in pharmacokinetic substudy A5121s.
The invention discloses a method for using 7-deazaadenine base as mother nucleus 18 An F-PET/CT tracer agent and a preparation method thereof. The invention firstly discloses a compound shown as a formula I or a pharmaceutically acceptable salt thereof, wherein R 1 、R 2 Each independently selected from H or C 1 ‑C 5 Alkyl groups of (a); x is independently selected from 11 C、 18 F、 15 O, or 13 And N is added. The invention also discloses a preparation method and application of the compound shown in the formula I. The invention successfully prepares the compound which takes 7-deazaadenine base as a mother nucleus 18 F-PET/CT tracer: 18 F-HX tracer. The experimental results show that the invention prepares 18 The F-HX tracer is uptake stable in tumors, more than 3 times that of muscle tissue. Accordingly, the present invention 18 The F-PET/CT tracer is expected to be applied to PET/CT imaging, and changes the situation of tracer deficiency in lung cancer.
PURPOSE:To can provide a composition capable of obtaining in an easy operation resin jacket crowns or bridges of excellent aesthetic nature and functionality, by combining an acrylic resin and inorganic fibrous whisker such as aluminum borate whisker at a specified proportion. CONSTITUTION:The composition, a combination of (A) 30-95 (pref. 30-45) wt.% of an acrylic resin and (B) 70-5 (pref. 70-55) wt.% of an inorganic filler, inorganic fibrous whisker (pref. alumina whisker, potassium titanate whisker or aluminum borate whisker, each as white whisker, esp. aluminum borate whisker). This composition is easy in its operation with technical skill, resulting in a cured product of excellent flexural strength, etc. This composition has advantages along with reliable mechanical strength, being directly usable for the dentine or enamel layer of a rigid resin crown.
Enzastaurin given orally (PO) once daily (QD). 1125 mg loading dose D(-)7 then 500 mg PO,QD with concomitant radiotherapy.